Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells

Journal of Cellular Physiology

Volumn 224, Issue 1, 2010, Pages 262-272

  Miki, Akiko ^a   Miki, Katsuaki ^a   Ueno, Shinji ^a   Wersinger, Delphine M Bonnet ^a   Berlinicke, Cynthia ^a   Shaw, Gillian C ^a   Usui, Shinichi ^a   Wang, Yuxia ^a   Zack, Donald J ^a   Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR; 3 (4 DIMETHYLAMINOBENZYLIDENE) 1,3 DIHYDROINDOL 2 ONE; 3-(4-DIMETHYLAMINOBENZYLIDENE)-1,3-DIHYDROINDOL-2-ONE; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; ELECTRORETINOGRAM; MOUSE; NERVE CELL; NONHUMAN; PHOTORECEPTOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION; WILD TYPE; ANIMAL; C57BL MOUSE; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ELECTRORETINOGRAPHY; GENETICS; INJECTION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHOTORECEPTOR CELL; RETINA GANGLION CELL; RETINA NEOVASCULARIZATION; TIME; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRORETINOGRAPHY; INDOLES; INJECTIONS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHORYLATION; PHOTORECEPTOR CELLS, VERTEBRATE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETINAL GANGLION CELLS; RETINAL NEOVASCULARIZATION; SIGNAL TRANSDUCTION; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952509760     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22129     Document Type: Article

References (33)

1. Barres BA, Chun Linda LY. 1993. Purification of rat retinal ganglion cells by immunopanning. Neuroprotocols 2:201-204.
2. Bocker-Meffert S, Rowenstiel P, Rohl C, Warneke N, Held-Feindt J, Sievers J, Lucius R. 2002. Erythropoietin and VEGF promote neural outgrowth from retinal explants in postnatal rats. Invest Ophthalmol Vis Sci 43:2021-2026. (Pubitemid 34587056)
3. Bonnet D, Garcia M, Vecino E, Lorentz JG, Sahel J, Hicks D. 2004. Brain-derived neurotrophic factor signalling in adult pig retinal ganglion cell neurite regeneration in vitro. Brain Res 1007:142-151. (Pubitemid 38520182)
4. Bradford RL, Wang C, Zack DJ, Adler R. 2005. Roles of cell-intrinsic andmicroenvironmental factors in photoreceptor cell differentiation. Dev Biol 286:31-45.
5. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, the Anchor Study Group. 2006. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-1444.
6. Campochiaro PA. 2004. Ocular neovascularisation and excessive vascular permeability. Expert Opin Biol Ther 4:1395-1402.
7. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD,Ying H, Do DV, Quinlan E, Zimmer-Galler I, Haller JA, Solomon S, Sung JU, Hadi Y, Janjua KA, Choy DF, Arron JR. 2008. Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator. Mol Ther 16:791-799.
8. Chan F, Bradley A,Wensel TG, Wilson JH. 2004. Knock-in human rhodopsin-GFP fusions as mouse models for human disease and targets for gene therapy. Proc Natl Acad Sci USA 101:9109-9114.
9. Chang B, Hawes NL, Hurda RE, Davisson MT, Nusinowitz S, Heckenlively JR. 2002. Retinal degeneration mutants in the mouse. Vision Res 42:517-525.
10. Gargini C, Terzibasi E, Mazzoni F, Strettoi E. 2007. Retinal organization in the retinal degeneration 10 (rd10) mutant mouse: A morphological and ERG study. J Comp Neurol 500:222-238.
11. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. 1998. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 30-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336-30343.
12. Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, Recchia FM. 2008. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration. A report of the American Academy of Ophthalmology. Ophthalmology 115:1837-1846.
13. Jin KL, Mao XO, Greenberg DA. 2000. Vascular endothelial growth factor: Direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA 97:10242-10247.
14. Kendall RL, Rutledge RZ, Mao X, Tebben AJ, Hungate RW, Thomas KA. 1999. Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues. J Biol Chem 274:6453-6460.
15. Kerrison JB, Lewis RN, Otteson DC, Zack DJ. 2005. Bone morphogenetic proteins promote neurite outgrowth in retinal ganglion cells. Mol Vis 11:208-215.
16. Kilic U, Kilic E, Jarve A, Guo Z, Spudich A, Bieber K, Barzena U, Bassetti CL, Marti HH, Hermann DM. 2006. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neuosci 26:12439-12446.
17. Komeima K, Rogers BS, Lu L, Campochiaro PA. 2006. Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natil Acad Sci USA 103:11300-11305.
18. Komeima K, Rogers BS, Campochiaro PA. 2007. Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol 213:809-815.
19. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML. 2007. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130:691-703.
20. Mori K, Duh E, Gehlbach P, Ando A, Takahashi K, Pearlman J, Mori K, Yang HS, Zack DJ, Ettyreddy D, Brough DE, Wei LL, Campochiaro PA. 2001. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 188:253-263.
21. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA. 2006. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 142:961-969.
22. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT. 2007. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171:53-67.
23. Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W, Zack DJ, Campochiaro PA. 1997. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: A new model of intraretinal and subretinal neovascularization. Am J Pathol 151:281-291. (Pubitemid 27283979)
24. Okoye G, Zimmer J, Sung JPG, Deering T, Nambu N, Hackett SF, Melia M, Esumi N, Zack DJ, Campochiaro PA. 2003. Increased expression of BDNF preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage. J Neuosci 23:4164-4172. (Pubitemid 36958436)
25. Ozaki H, Seo M-S, Ozaki K, Yamada H, Yamada E, Hofmann F, Wood J, Campochiaro PA. 2000. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 156:679-707. (Pubitemid 30643824)
26. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS,Kaiser PK, Chung CY, Kim RY, the Marina Study Group. 2006. Ranibizumab for neovascular age-relatedmacular degeneration.N Engl J Med 355:1419-1431.
27. Saint-Geniez M, Raharaj ASR, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA. 2008. Endogenous VEGF is required for visual function: Evidence for a survival role on Muller cells and photoreceptors. Plos One 3:e3554, 1-13.
28. Saishin Y, Saishin Y, Takahashi K, Melia M, Vinores SA, Campochiaro PA. 2003. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. J Cell Physiol 195:210-219.
29. Seo M-S, Kwak N, Ozaki H, Yamada H, Okamoto N, Fabbro D, Hofmann F, Wood JM, Campochiaro PA. 1999. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 154:1743-1753. (Pubitemid 29262856)
30. Sun L, Tran N, Tang F, App H, Hirth P, McMahon G, Tang C. 1998. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem 41:2588-2603.
31. Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, Kaneko H, Albuquerque RJC, Dridi S, Saito K, Raisler BJ, Budd SJ, Geisen P, Munitz A, Ambati BK, Green MG, Ishibasi T, Wright JD, Humbles AA, Gerard CJ, Ogura Y, Pan Y, Smith JR, Grisanti S, Hartnett ME, Rothenberg ME, Ambati J. 2009. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 460:225-230.
32. Tobe T, Okamoto N, Vinores MA, Derevjanik NL, Vinores SA, Zack DJ, Campochiaro PA. 1998. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci 39:180-188. (Pubitemid 28040477)
33. Ueno S, Pease ME, Wersinger DMB, Masuda T, Vinores SA, Licht T, Zack DJ, Quigley H, Keshet E, Campochiaro PA. 2008. Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol 217:13-22.